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Abstract
Background:  This study investigated mechanisms of altered fibroblast collagen production
induced by polyunsaturated fatty acids. 3T3-Swiss fibroblasts were grown in medium containing
either eicosapentaenoic or arachidonic acid. The effects of nuclear factor-kappaB activation by
lipopolysaccharide on inducible nitric oxide synthase, nitric oxide, prostaglandin E2, collagen
production, and in-vitro wound healing were studied.
Results: Eicosapentaenoic acid treated cells produced less prostaglandin E2 but had increased
inducible nitric oxide synthase expression, nitric oxide production, collagen formation, and
recoverage area during in-vitro wound healing than cells treated with arachidonic acid. Activation of
nuclear factor-kappaB with lipopolysaccharide increased inducible nitric oxide synthase expression,
the production of nitric oxide, prostaglandin E2, collagen, and the in-vitro wound recoverage area.
The nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester, decreased
lipopolysaccharide-induced nitric oxide, but the amount of nitric oxide was greater in
eicosapentaenoic acid treated cells. NG-nitro-L-arginine methyl ester plus lipopolysaccharide
treatment increased collagen production and cellular recoverage area while treatment with NG-
nitro-L-arginine methyl ester alone decreased it in wounded fibroblasts.
Conclusion: The activation of the NF-κB pathway and PGE2 can be linked by the cross-talk of
iNOS and NO in the PUFA altered fibroblast collagen production and wound healing. Additional
studies are needed to determine how polyunsaturated fatty acids can be used as adjuvants in
combination with other treatments (i.e, drugs) to design therapies to either enhance healthy
collagen production or inhibit production and reduce fibrosis.
Background
The purpose of this research was to test the hypothesis
that polyunsaturated fatty acids can alter collagen forma-
tion during in-vitro healing by changing iNOS expression
and NO production, which have cross-interaction with
the nuclear transcription factor kappaB (NF-κB) pathway
and PGE2. The control of collagen formation for optimal
healing in tissues and organs is essential for numerous
diseases [1-3]. The healing of skin and connective tissues
such as ligaments require enhanced and effective produc-
tion of healthy collagen for strength and to shorten the
recovery time, but without scarring. However, collagen
formation in injured vital organs needs to be minimized
to prevent fibrosis and subsequent loss of organ function.
Both enhanced and reduced collagen formation likely
have common regulatory mechanisms that remain to be
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elucidated. Multiple cellular and extracellular factors can
influence collagen formation, such as nitric oxide [4],
PGE2 [5], as well as growth factors [6] and matrix metallo-
proteinases [7]. Therefore, potential therapies to control
healing may require an approach targeting multiple mol-
ecules or mechanisms.
Our previous studies showed that polyunsaturated fatty
acids (PUFA) alter collagen production in avian chondro-
cytes [8], porcine medial collateral ligament fibroblasts
[9], and murine 3T3-Swiss fibroblasts [5]. Eicosapentae-
noic acid (EPA, 20:5 n-3) treated porcine medial collateral
ligament fibroblasts produced more collagen than those
treated with arachidonic acid (AA, 20:4 n-6) [9]. In
murine 3T3-Swiss fibroblasts, we have observed that col-
lagen production could be regulated by exposure to differ-
ent n-6: n-3 PUFA ratios and these effects were mediated,
in part, by PGE2 and changes in the signaling via the dif-
ferent PGE receptor subtypes [5].
Since many collagen formation associated genes have pro-
moter or enhancer elements for NF-κB [10], we studied
the different response of NF-κB related genes to EPA and
AA treatments in 3T3-Swiss fibroblasts by a gene profiling
system [11]. Treatments with lipopolysaccharide (LPS),
an NF-κB inducer, stimulated increased expression of sev-
eral genes in the NF-κB pathway that are linked collagen
production (i.e, interleukin-6 and inducible nitric oxide
synthase).
The activated NF-κB dimer binds to the 5'-flanking region
of the iNOS promoter and induces iNOS formation [12].
Inducible nitric oxide synthase (iNOS) and nitric oxide
(NO) have an important role in collagen formation dur-
ing wound healing [13,14]. Inhibition of NO synthase
significantly decreased collagen synthesis in wound
fibroblasts [13]. Dermal fibroblasts from iNOS-knock out
murine fibroblasts proliferated more slowly and synthe-
sized less collagen, and NO donors restored the collagen
synthesis to normal level [15]. Another study implicated a
role for NO in PGE2 formation and collagen deposition in
rats [16]. Therefore, endogenous iNOS and NO may link
the NF-κB pathway to PGE2 and regulate collagen forma-
tion during wound healing.
Results
Real-time RT-PCR for iNOS mRNA
The transcriptional level of iNOS mRNA was determined
by the real-time RT-PCR (Figure 1). The expression of
iNOS mRNA can be altered by stimulation of the NF-κB
pathway. Incubation with the NF-κB pathway inducer,
lipopolysaccharide (LPS, 10 µg/ml), significantly (P  <
0.01) increased the expression of iNOS mRNA in both
arachidonic acid (AA, 20:4 n-6) and eicosapentanoic acid
(EPA, 20:5 n-3) treated normal or wounded 3T3-Swiss
fibroblasts. However, the EPA-treated fibroblasts were
more responsive to induction of the NF-κB pathway than
AA-treated cells. Activation of the NF-κB pathway in EPA-
treated cells with LPS resulted in significantly increased (P
< 0.001) transcription of iNOS mRNA compared to AA-
treated cells. The addition of the nitric oxide synthase
inhibitor, NG-nitro-L-arginine methyl ester (L-NAME, 10-
7 M) resulted in a significant increase (P < 0.05) in the
transcription of iNOS mRNA only in EPA-treated fibrob-
lasts with LPS stimulation.
Quantification of nitrite
A stable end product of NO synthesis, nitrite, was meas-
ured to determine the NO concentration (Figure 2). The
Real-time RT-PCR for iNOS mRNA expression in 3T3-Swiss  fibroblasts n = 3, ± SD) Figure 1
Real-time RT-PCR for iNOS mRNA expression in 
3T3-Swiss fibroblasts n = 3, ± SD). The expression of 
iNOS mRNA can be altered by stimulation of the NF-κB 
pathway or inhibition of nitric oxide synthase in 3T3-Swiss 
fibroblasts. EPA treated fibroblasts were more sensitive to 
the changes of NF-κB pathway than AA treated cells. Cells 
were incubated for 48 hr with bovine serum albumin alone as 
control or bovine serum albumin-soap loaded fatty acids (25 
µM). Medium was then replaced with fresh fatty acid 
enriched medium containing lipopolysaccharide (LPS, 10 µg/
ml) with or without NG-nitro-L-arginine methyl ester (L-
NAME, 10-7 M) for another 24 hr. The wound was created 
after initial 48 hr treatments in duplicate set of plate with or 
without LPS. Cells were harvested at 24 hr post wounding 
and real-time RT-PCR was performed. The results were pre-
sented as the percentage of iNOS to β-actin mRNA expres-
sion. Bars with different letters are significantly different (P < 
0.05). EPA, eicosapentaenoic acid; AA, arachidonic acid; LPS, 
lipopolysaccharide; L-NAME, NG-nitro-L-arginine methyl 
ester.
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production of nitrite can be changed by altering the activ-
ity of the NF-κB pathway and nitric oxide synthase. EPA-
treated normal fibroblasts without LPS stimulation pro-
duced more nitrite than control or AA-treated fibroblasts.
However, when stimulated by LPS, EPA-treated normal
fibroblasts produced significantly (P < 0.05) less nitrite
than control or AA-treated cells. Treatment with L-NAME
significantly reduced LPS-induced nitrite production, and
EPA-treated cells produced more nitrite than AA-treated
cells. Wounded and LPS stimulated cells decreased nitrite
production for all treatments compared to LPS alone, but
EPA-treated fibroblasts produced less nitrite than AA-
treated or control cells.
Quantification of PGE2
Activation of NF-κB pathway by LPS in 3T3-Swiss fibrob-
lasts significantly increased (p < 0.05) the production of
PGE2 over control levels for all groups (Figure 3). Both
basal and LPS stimulated amounts of PGE2 were lowest in
EPA-treated fibroblasts compared to the control and AA-
treated cells. The addition of the nitric oxide synthase
inhibitor, L-NAME, to LPS stimulated fibroblasts
decreased PGE2 production to basal levels for all groups.
Wounding of LPS stimulated cells did not significantly
change the amount of PGE2 produced by cells when com-
pared with those stimulated by LPS alone.
Collagen formation
Wounded fibroblasts without any PFA treatment
increased both collagen production (CP) and collagen as
a percentage of total proteins (C-PTP) compared to
NO production in 3T3-Swiss fibroblasts (n = 3, ± SD) Figure 2
NO production in 3T3-Swiss fibroblasts (n = 3, ± SD). 
Cells were incubated for 48 hr with bovine serum albumin 
alone as control or bovine serum albumin-soap loaded fatty 
acids (25 µM). Medium was then replaced with fresh fatty 
acid enriched medium containing lipopolysaccharide (LPS, 10 
µg/ml) with or without NG-nitro-L-arginine methyl ester (L-
NAME, 10-7 M) for another 24 hr. The wound was created 
after initial 48 hr treatments in a duplicate set of plate with 
LPS treatments. Culture supernatants (100 µl) were col-
lected at 24 hr post wounding and quantification of nitrite 
was performed. The results were presented as the nitrite 
concentration (µM). Bars with different letters are signifi-
cantly different (P < 0.05). EPA, eicosapentaenoic acid; AA, 
arachidonic acid; LPS, lipopolysaccharide; L-NAME, NG-nitro-
L-arginine methyl ester.
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PGE2 production in 3T3-Swiss fibroblasts n = 3, ± SD) Figure 3
PGE2 production in 3T3-Swiss fibroblasts n = 3, ± SD). 
The addition incubation of nitric oxide synthase inhibitor 
decreased the LPS induced PGE2 production in 3T3-Swiss 
fibroblasts. Cells were incubated for 48 hr with bovine serum 
albumin alone as control or bovine serum albumin-soap 
loaded fatty acids (25 µM). Medium was then replaced with 
fresh fatty acid enriched medium containing lipopolysaccha-
ride (LPS, 10 µg/ml) with or without NG-nitro-L-arginine 
methyl ester (L-NAME, 10-7 M) for another 24 hr. The 
wound was created after initial 48 hr treatments in duplicate 
set of plate with or without LPS. Culture supernatants were 
collected at 24 hr post wounding and the quantification of 
PGE2performed. The results were presented as the PGE2 
concentration (pg/ml). Bars with different letters are signifi-
cantly different (P < 0.05). EPA, eicosapentaenoic acid; AA, 
arachidonic acid; LPS, lipopolysaccharide; L-NAME, NG-nitro-
L-arginine methyl ester.
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control (non-wounded, no PFA treatment) fibroblasts
(Table 2). However, wounded fibroblasts treated with LPS
produced less collagen and C-PTP than the control cells
with LPS stimulation. Treatment with L-NAME alone
decreased collagen production in control fibroblasts,
while the additional of L-NAME plus LPS produced more
collagen and had more collagen as a percentage of total
protein in both control and wounded fibroblasts. The
combination treatments of EPA, L-NAME and LPS pro-
duced higher CP and C-PTP than treatments of AA, L-
NAME and LPS in normal fibroblasts.
In-vitro wounding assay
The cellular recoverage area in wounded fibroblasts
changed by the treatments of LPS, nitric oxide synthase
inhibitor, cyclooxygenase (COX) inhibitor, and PFA (Fig-
ure 4). After 24 hr post wounding, LPS activation of the
NF-κB pathway increased the percentage of cellular recov-
erage area compared to the control. The treatment of L-
NAME alone decreased the percentage of cellular recover-
age area in all groups while the treatment of L-NAME plus
LPS increased the cellular recoverage area compared to
LPS treatment alone. Administration of indomethacin, a
cyclooxygenase inhibitor, increased the cellular recover-
age area in LPS stimulated fibroblasts. The treatments of
EPA and AA alone both increased the recoverage area
compared to the control. EPA-treated fibroblasts with LPS
had a higher the percentage of cellular recoverage area
than the AA plus LPS treated cells, with or without other
treatments.
Discussion
Polyunsaturated fatty acids affect the formation of numer-
ous mediators of inflammation, such as eicosanoids and
cytokines [9]. Thus, dietary fatty acids, those mobilized
from cellular phospholipids or triacylglycerols stored in
adipose tissue, and topical applications [18] can all poten-
tially influence wound healing. A limited number of stud-
ies have examined the effects of dietary or topical
applications of PUFA on wound healing. A cutaneous
wound healing study found that rats fed a diet enriched in
n-3 fatty acids produced wounds that were weaker in ten-
sile strength compared to those from rats fed a diet con-
taining n-6 fatty acids [19]. Cutaneous wounds in dogs fed
an n-3 enriched diet had reduced epithelialization and
contraction of open wounds and less edema in sutured
Table 1: Primers for iNOS and β-actin. Primers for iNOS and β-actin were designed by Primer Express®2.0 (Applied Biosystems). 
iNOS, inducible nitric oxide synthase.
Gene Genebank accession # Start positions Primer sequences (5' ? 3') Amplicon length (bp)
iNOS U43428 2407 AGGGAATCTTGGAGCGAGTTGT 103
2509 AGCCTCTTGTCTTTGACCCAGT
β-actin X03672 886 TGGAATCCTGTGGCATCCATGA 91
976 AGCACTGTGTTGGCATAGAGGT
Table 2: Collagen formation in 3T3-Swiss fibroblasts (n = 3, ± SD). Cells were incubated for 48 hr with bovine serum albumin alone as 
control or bovine serum albumin-soap loaded fatty acids (25 µM). The wound was then created and the medium was then replaced 
with fresh fatty acid enriched medium containing 50 µM ascorbic acid and 5 µCi of 3H-proline with or without lipopolysaccharide (LPS, 
10 µg/ml) and NG-nitro-L-arginine methyl ester (L-NAME, 100 nM). A duplicate set of plates was made without wounding. Cells were 
harvested at 24 hr post wounding and assayed for collagen, total protein and DNA. The amount of collagen is expressed as DPM from 
3H-proline per µg of DNA. Mean values within rows having different superscripts are significantly different (P < 0.05) by 1-way ANOVA 
and Tukey test. EPA, eicosapentaenoic acid; AA, arachidonic acid; LPS, lipopolysaccharide; L-NAME, NG-nitro-L-arginine methyl 
ester.
Treatments Collagen production (CP) (DPM/µg DNA amount) Collagen as a percentage of total protein (C-PTP) (%)
Control 2419.6 ± 318.1a 18.7 ± 1.6a
Wound 3044.8 ± 269.2b 21.8 ± 1.5b
LPS 3953.3 ± 57.3c 26.5 ± 0.8c
L-NAME 1225.6 ± 270.7d 11.4 ± 2.7d
LPS + Wound 2650.3 ± 146.9ab 19.0 ± 1.8ab
LPS + L-NAME 5393.7 ± 583.4e 37.5 ± 3.3e
LPS + L-NAME + EPA 6580.2 ± 418.3e 42.4 ± 5.6e
LPS + L-NAME + AA 3511.3 ± 561.4c 26.7 ± 4.0cLipids in Health and Disease 2005, 4:14 http://www.lipidworld.com/content/4/1/14
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wounds after 5 days than dogs fed a diet enriched in n-6
fatty acids. However, the n-3 diet did not appear to have a
negative effect on wound healing [20]. A more recent
study found that topical application of oleic acid
(monounsaturated n-9 fatty acid) to surgically induced
skin wounds in mice resulted in more rapid wound clo-
sure than applications of linolenic acid (18:3, n-3) or lino-
leic acid (18:2, n-6) [18]. The topical application of
linolenic acid also resulted in an increased amount of con-
nective tissue fibers compared to other fatty acid treat-
ments. These limited studies suggest that in order to take
advantage of the inflammation mediating properties of
PUFA and use them as adjuvants in the healing process, it
may be necessary to use the different classes of PUFA
selectively during the stages of wound healing. Wound
healing consists of an inflammatory phase, a proliferative
(fibroblastic) phase, and a remodeling (maturation)
phase [21,22]. In addition, the type of wound (e.g., acute
or chouronic) and patient (e.g., diabetic, burn injured, or
immunosuppressed) will require matching the appropri-
ate PUFA to the particular stage of wound healing. For
example, in immunosuppressed patients, a PUFA that
enhances inflammation in the early stages may be needed
to stimulate the healing process.
A component of optimal healing is regulation of collagen
formation. Favorable collagen formation includes both
enhanced collagen production for healing connective tis-
sues and diminished formation in vital organs to mini-
mize fibrosis. Our previous studies revealed that
polyunsaturated fatty acids affected a number of media-
tors and pathways involved in collagen formation [5,9].
Many collagen formation associated genes, such as IL-6
and iNOS, have promoter or enhancer elements for NF-κB
[23,24]. These genes provide ideal targets to connect vari-
ous pathways involved in PUFA influenced collagen
formation. The present paper studied the link between
NF-κB pathway generated iNOS and nitric oxide (NO) in
PUFA altered collagen formation, and the association
with PGE2 production. Our hypothesis in the present
study is that polyunsaturated fatty acids can alter collagen
formation during in-vitro  healing by changing iNOS
expression and NO production, which have cross-interac-
tion with the NF-κB pathway and PGE2 (Figure 4, 5).
NO is synthesized from the terminal guanidine nitrogen
atom of L-arginine by nitric oxide synthase (NOS) and
involved in many biological functions [25]. The inducible
isoform of NOS (iNOS) is regulated primarily at the tran-
scriptional level and contributes to most of the NO pro-
duced compared to the other isoforms [26]. The NF-κB
signaling pathway regulates promoter regions and
induces iNOS transcription [12]. In the present study
using real-time RT-PCR, activation of the NF-κB pathway
by LPS increased the transcription of iNOS mRNA in 3T3-
Swiss fibroblasts. The increase was greatest in EPA-treated
fibroblasts. Other researchers reported that NO can also
regulate iNOS transcription through a negative feedback
by inhibiting NF-κB binding to DNA [27]. In our experi-
ments, the addition of a small amount of the nitric oxide
synthase inhibitor, L-NAME, increased the transcription
of iNOS mRNA only in EPA plus LPS treated normal
fibroblasts. However, the increased iNOS expression in
EPA plus LPS treated cells did not result in increased nitric
oxide (nitrite) production, and EPA plus LPS treated cells
produced less nitric oxide than control or AA treated cells.
The decreased amount of nitric oxide with EPA plus LPS
treatment may enhance iNOS expression due to decreased
negative feedback on NF-κB binding to DNA (Figure 4, 5).
In-vitro wounding assay in 3T3-Swiss fibroblasts (n = 3, ± SD) Figure 4
In-vitro wounding assay in 3T3-Swiss fibroblasts (n = 
3, ± SD). The addition treatment of L-NAME to LPS 
increased the percentages of cellular recover area while the 
treatment of L-NAME alone decreased it in wounded 3T3-
Swiss fibroblasts. When stimulated with LPS, EPA treated 
fibroblasts had higher the percentage of cellular recover area 
than the AA treated cells. Cells were incubated for 48 hr 
with bovine serum albumin alone as control or bovine serum 
albumin-soap loaded fatty acids (25 µM). Then wound was 
created and the medium was replaced with fresh fatty acid 
enriched medium containing lipopolysaccharide (LPS, 10 µg/
ml), NG-nitro-L-arginine methyl ester (L-NAME, 10-7 M) and 
indomethacin (10-8 M) for another 24 hr. Multiple photo-
graphs of the wound were obtained and the percentage of 
cellular recover areas were determined. Bars with different 
letters are significantly different (P < 0.05). EPA, eicosapen-
taenoic acid; AA, arachidonic acid; LPS, lipopolysaccharide; L-
NAME, NG-nitro-L-arginine methyl ester; INDO, 
indomethacin.
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The observation that increased iNOS expression in EPA-
treated cells does not lead to increased NO production,
may be explained by altered post-transcriptional regula-
tion that leads to reduced synthesis of iNOS protein and
thus decreased NO production.
Reduced NO in EPA treated cells, even though there is
increased transcription of iNOS mRNA, can also be linked
to PGE2 production in these cells. The amount of PGE2
produced by the 3T3 fibroblasts was inversely related to
the amount of nitric oxide produced. PGE2 will bind to
PGE receptors (EP1, EP2, EP3, and EP4) that activate sig-
naling by protein kinase C (PKC) or cyclic AMP (cAMP).
Cells treated with AA are mainly responsive to signaling
from the EP1 receptor (PKC signaling), whereas EPA-
treated cells are mainly responsive to EP2 and EP4 signal-
ing (cAMP signaling) [5]. Arachidonic acid alone has been
shown to function as a secondary messenger and activate
Proposed model for regulation of collagen formation in these experiments Figure 5
Proposed model for regulation of collagen formation in these experiments. 1. Activation of the nuclear factor-κB 
(NF-κB) signaling pathway by lipopolysaccharide. 2. NO can inhibit the binding of NF-κB family members to target DNA. 3. 
NF-κB family binding to DNA and transcription of iNOS mRNA. 4. L-NAME inhibits the production of NO from iNOS. 5. NO 
regulates PGE2 production divergently through activation of COX isoforms. 6. Indomethacin inhibits COX and reduces 
PGE2production. 7. Collagen production and wound healing processes are changed by the activation of different PGE2 recep-
tors subtypes and second messengers. LPS, lipopolysaccharide; Tlr4, Toll-like receptor 4; Traf6, Tumor necrosis factor recep-
tor-associated factor 6; IκB, Inhibitor of kappa light polypeptide gene enhancer in B-cell; NF-κB, nuclear transcription factor 
kappaB; iNOS, inducible nitric oxide synthase; L-NAME, NG-nitro-L-arginine methyl ester; NO, nitric oxide; COX, cyclooxy-
genase; INDO, indomethacin; PKC, protein kinase C; cAMP, cyclic adenosine monophosphate.
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PKC. The increased amount of PGE2 in AA-treated cells
and stimulation of the PKC signaling pathway via the EP1
receptor (e.g., PKC activation) could affect post-transla-
tional synthesis of iNOS protein. Other studies identified
a role for PKC in the induction of iNOS by the NF-κB
pathway in murine 3T3 fibroblasts [28] and the nitric
oxide action on angiogenesis [29].
Nitric oxide regulates PGE2 production in a divergent
manner. Nitric oxide stimulated PGE2 release in macro-
phages [30,31] while endogenous NO inhibited PGE2
production in LPS-stimulated macrophages [32]. The dual
effect of NO on PGE2 production may be due to the
different effects on cyclooxygenase (COX) isoforms. Study
of COX isoform deficient murine fibroblasts revealed that
NO changed PGE2 production by activating COX-1 but
inhibiting COX-2 [30]. Other studies showed that low
concentrations of nitric oxide attenuate PGE2 production
induced by LPS, in part, due to decreased expression of
COX-2 protein [33]. However, LPS activation of the NF-
κB pathway can influence COX-2 gene expression by
directly altering COX-2 mRNA transcription [34]. Our
results showed that inhibition of NO with L-NAME,
decreased LPS-induced PGE2 production in normal 3T3-
Swiss fibroblasts. Thus, PGE2production in 3T3-Swiss
fibroblasts may be regulated at the COX-2 transcription
level through the NF-κB pathway or the COX-2 post-trans-
lational level through the production of NO derived via
nitric oxide synthase. The combination of PUFA treatment
(EPA) plus blocking of nitric oxide production with L-
NAME, resulted in a synergistic effect that enhanced colla-
gen production compared to control fibroblasts.
The suppression of type I collagen gene expression by
PGE2 can be mediated by both altering the amount and
steady-state of collagen mRNA [35,36]. Interestingly, inhi-
bition of iNOS activity has been shown to both slow col-
lagen production in the healing process and also favor
collagen deposition and development of fibrosis [37]. It
was hypothesized that NO scavenged reactive oxygen
species by formation of peroxynitrite, and iNOS inhibi-
tion blocked NO formation and contributed to the devel-
opment of fibrosis [37]. Therefore, appropriate induction
of iNOS from the NF-κB signaling pathway may be a crit-
ical mechanism for controlling collagen formation in
both fibrosis and proper wound healing.
Changes in collagen formation have also been correlated
to the concentration of NO produced. Collagen produc-
tion (CP) and collagen as a percentage of total protein (C-
PTP) was increased in LPS and interferon-γ (IFN-γ) incu-
bated wound derived murine fibroblasts [13]. Additional
treatments of NO synthase inhibitors decreased the CP
and C-PTP in the same study. However, LPS and IFN-γ
together, decreased, while inhibitors of NO restored the
collagen production in human small intestinal lamina
propria fibroblasts [38]. Another study in normal rat skin
fibroblasts showed that a nitric oxide donor at low con-
centration enhanced, but at higher concentration reverted
collagen synthesis back to control levels [4]. Dermal
fibroblasts from iNOS-knock out mice proliferated more
slowly and synthesized less collagen [15], and transfec-
tion with iNOS enhanced the collagen production in a
cutaneous wounded rat model [39]. In our experiments,
LPS stimulated the expression of iNOS mRNA, NO pro-
duction, and collagen synthesis in 3T3-Swiss fibroblasts.
The additional incubation of small amount of L-NAME to
LPS decreased the NO production to a low level but
increased the expression of iNOS mRNA and the collagen
production.
Healing fibroblasts are phenotypically characterized by
changes in collagen production, cell proliferation, and
migration. Wound cells have been shown to increase the
expression of iNOS and production of NO in various
models [13,40]. Inhibition of iNOS delayed the reepithe-
lialization in cutaneous wound repair [41]. The delayed
wound repair in iNOS knockout mice was reversed by
iNOS gene transfer [42]. Interestingly, the role of nitric
oxide on cell proliferation after wounding is
concentration-dependent [4]. At low concentration, NO
promoted cell proliferation in murine fibroblasts [43],
while at higher concentrations, NO decreased the prolifer-
ation of rat dermal skin fibroblasts [4]. The present study
showed that the treatment of L-NAME alone inhibited the
NO production and decreased the percentage of cellular
recoverage area in 3T3-Swiss fibroblasts. However, the
additional treatment of L-NAME to fibroblasts stimulated
by LPS increased cell proliferation and migration com-
pared to the LPS treatments alone. L-NAME alone may
block the effect of nitric oxide at low concentration while
the addition of L-NAME plus LPS decreased the LPS
induced NO to a low concentration and increased the col-
lagen formation, cell proliferation, and migration.
Indomethacin, a cyclooxygenase inhibitor, increased the
percentage of cellular recoverage area in fibroblasts with
LPS stimulation. The decreased PGE2  induced by
indomethacin also stimulated wound healing in 3T3-
Swiss fibroblasts.
In summary, we demonstrated that iNOS and NO provide
a cross-talk between the activation of the NF-κB pathway
and PGE2 in the PUFA altered fibroblast collagen produc-
tion and wound healing. The use of PUFA for regulation
of collagen formation in wound healing or fibrosis will
require additional experiments in order to determine how
they may be used as adjuvants. Most likely it will be nec-
essary to use a particular class of fatty acids (e.g., n-3, n-6,
n-9) appropriate to the type of wound and stage of wound
healing. In addition, use of fatty acids in combinationLipids in Health and Disease 2005, 4:14 http://www.lipidworld.com/content/4/1/14
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with selective targeting of transcription factors and medi-
ators (e.g., stimulation or inhibition) that regulate
collagen formation will provide the level of control neces-
sary to adapt the treatment protocol to the type of wound.
Methods
Reagents
Reagents were purchased from Sigma-Aldrich, St. Louis,
MO, unless specified otherwise.
Cell culture and fatty acid enrichment
Mouse fibroblast (3T3-Swiss albino; American Type Cul-
ture Collection CCL-92, Rockville, MD) were maintained
as subconfluent monolayers in six-well plates (Corning
Costar, Cambridge MA) with Dulbecco's modified Eagle's
medium (DMEM), 4 mM L-glutamine, 1.5 g/L sodium
bicarbonate, 4.5 g/L glucose, and 10% bovine calf serum
(Hyclone, Logan, UT). Subconfluent cultures grown for
24 hr in maintenance medium were washed twice and
changed to fresh medium minus calf serum. In place of
serum, the control medium was supplemented with 5 mg/
100 ml of fatty acid free bovine serum albumin (BSA);
and the fatty acid enriched test media were supplemented
with BSA-loaded fatty acid soaps of arachidonic acid (AA,
20:4 n-6) or eicosapentaenoic acid (EPA, 20:5 n-3) (Nu-
Chek Prep, Elysian, MN) to a final concentration of 25
µM. Cells were grown for 48 hr in the test media prior to
addition of treatments described below.
In vitro wound assay
An in vitro wound healing assay was used to evaluate the
migration and proliferation of 3T3-Swiss fibroblast as pre-
vious studies [9]. Briefly, a sterile pipette tip was used to
make a 0.5-mm-wide wound by streaking across a
monolayer of 3T3 Swiss fibroblasts. The wound was cre-
ated when the cells were about 80% confluent after the
initial 48 hr polyenoic fatty acid (PFA) enrichment and
the migration of fibroblasts into the wound was measured
at 24 hr post wounding. Multiple photographs of the
wound were obtained by phase contrast microscopy, and
the mean areas of cell recoverage for each sample were
determined with image analysis software (Optimas 6.1,
Media Cybernetics, Silver Spring, MD). The percentage of
cellular recoverage area to the whole wound area was
measured to evaluate the combined effects of cell prolifer-
ation and migration.
A similar set of plates was used to perform the real-time
RT-PCR of iNOS, quantification of nitrite and PGE2, and
collagen synthesis. For real-time RT-PCR and the quantifi-
cation of nitrite and PGE2, the following protocol was
used. After the initial 48 hr PFA enrichment, the media
was changed with fresh fatty acid enriched medium con-
taining Eshericia coli O55:B5 lipopolysaccharide (LPS, 10
µg/ml) with or without NG-nitro-L-arginine methyl ester
(L-NAME, 10-7 M) and indomethacin (INDO, 10-8 M).
Lipopolysaccharide is used to activate the NF-κB pathway
and mimic some aspects of in vivo inflammation. For col-
lagen formation, after the initial 48 hr polyenoic fatty acid
(PFA) enrichment, the media was replaced with fresh fatty
acid enriched medium containing 50 µM ascorbic acid
and 5 µCi of 3H-proline (Amersham, Arlington Heights
IL) with or without treatments. At 24 hr post wounding, a
portion of the media was collected or the cells were har-
vested. Parallel plates were also cultured with the same
treatments but without wounding. The cells for all treat-
ments used in these experiments had greater than 99%
viability based upon the standard trypan blue dye exclu-
sion test.
RNA isolation and cDNA synthesis
After cells were washed with Hank's balanced salt solution
and harvested, total RNA was isolated using a commer-
cially available kit (RNAqueous, Ambion, Austin, TX) and
digested with RNase-free DNase, as recommended by the
supplier. The concentration and purity of total RNA were
determined by measuring the optical density at 260 and
280 nm. The ratio of absorbance at 260 to 280 nm was
1.8–2.0. Two µg total RNA was reverse transcribed using a
cDNA synthesis Kit (iScript™ cDNA Synthesis Kit, Bio-Rad
Laboratories, Hercules, CA) following the manufacture's
instructions. Generated cDNA were diluted with RNA-free
water before usage.
Real-time RT-PCR
Synthesized cDNA encoding for murine iNOS and β-actin
(as endogenous control) were amplified and analyzed by
a real-time reverse transcription polymerase chain reac-
tion (real time RT-PCR) system (Applied Biosystems 7300
Real Time PCR System, Foster City, CA). The oligonucle-
otide primers were designed by Primer Express software
(Primer Express 2.0, Applied Biosystems) and ordered
from IDT (Integrated DNA Technologies, Coralville, IA).
The cDNA sequences were obtained from the Genebank
database as indicated in table 1. PCR amplifications were
performed according to the manufacture's protocol. Sam-
ples were prepared in a total volume of 50 µl containing 2
µl cDNA sample (diluted 1x, 10x, 100x, 200x), 25 µl SYBR
Green PCR Master Mix (Applied Biosystems, Foster City,
CA), 1 µl each primer, and 21 µl RNA-free water. For each
reaction, the polymerase was initiated at 50°C for 2 min
and 95°C for 10 min, and amplification was then per-
formed at 35 cycles of switching between 95°C for 15 sec-
onds, 55°C for 30 seconds, and 72°C for 15 seconds
followed by melting point analysis from 60°C to 95°C.
All samples were done in triplicate and the coefficient was
determined by creating a standard curve from plotting CT
values vs. the total RNA. The results were presented as the
mRNA expression percentage of iNOS to β-actin.Lipids in Health and Disease 2005, 4:14 http://www.lipidworld.com/content/4/1/14
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Quantification of nitrite
Nitrite (NO2-) in culture supernatants was measured to
determine the synthesis of NO as other studies [17]. Cul-
ture supernatants (100 µl) were mixed with an equal vol-
ume of Griess reagent (1% sulfanilamide, 0.1%
naphthylethylene diamine dihydrochloride and 2.5%
phosphoric acid) and incubated at the room temperature
with dimmed light for 10 min. Nitrite was measured at
550 nm by a microplate reader (EIA reader 2550, Bio-Rad,
Hercules, CA) using the double-distilled water as blank
and the sodium nitrite to generate a standard curve.
Quantification of PGE2
Assessment of total prostaglandin E2 (PGE2) amount from
the medium of 3T3-Swiss fibroblasts incubation was
preformed by an ELISA kit (Monoclonal prostaglandin E2
EIA Kit-514010; Cayman Chemical, Ann Arbor, MI),
according to the manufacturer's recommended protocol.
Collagen assay
Collagen was assayed as described previously [5]. The
media was collected and the cells washed twice with cold
phosphate buffered saline (PBS). The cells were pelleted
by centrifugation and the PBS wash combined with the
media fraction. The cell pellet was suspended in 1.0 ml of
ammonium hydroxide-Triton X-100 cell lysing solution
(AT solution). Following 15-minute incubation at 37°C,
750 µl of the lysate is combined with the media fraction.
The two fractions, cell and media, then underwent trichlo-
roaceticic acid (TCA) precipitation (equal volume of 20%
TCA added to the cell plus media fraction). The acid insol-
uble precipitate was then rinsed several times with 10%
TCA to remove free 3H-proline. The precipitate was redis-
solved in 0.05 N NaOH in 0.05 M TES buffer plus 0.005
M CaCl2 and half of the solution incubated for 6 hr at
37°C with protease-free Type VII collagenase (100 U/ mL)
in TES and the other half of the solution served as a con-
trol. Following the digestion, TCA was again added to pre-
cipitate the acid insoluble proteins; however, the collagen
fragments generated by collagenase treatment remain in
solution. The supernatant and precipitate were counted in
a scintillation counter and collagen, non-collagenous,
and total protein production reported as DPM/µg DNA.
DNA assay
The remaining 250 µl of the AT solution cellular-lysate
from the collagen synthesis assay was used for total DNA
determination. Picogreen, 50 µl (Molecular Probes,
Eugene OR) was added to 50 µl of lysate or to 50 µl of
known DNA standards and fluorescence of the dye bind-
ing to double stranded DNA was measured in a
spectofluorometer. A DNA standard curve was generated
by linear regression and sample DNA values was used to
obtain the unknown values.
Statistical analysis
Data were presented as means ± standard deviation (SD)
and analyzed by both one-way and two-way ANOVA
procedures of SAS (SAS Institute, Cary, NC). A Tukey test
was used to analyze significant main and interaction
effects. A P  value < 0.05 was considered statistically
significant.
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